# De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

> **NCT06557421** · PHASE2 · RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06557421
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-04
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06557421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06557421, "De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06557421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*